Nevertheless, many others have also shown that patients who do not express PD-L1 in the tumor microenvironment may also benefit from anti-PD-1/PD-L1-based immunotherapy [29, 30, 32, 33]. The gene discussed is PDCD1; the disease is neoplasm.